

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

OMB APPROVAL

OMB Number: 3235-0104
 Estimated average burden hours per response: 0.5

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Merck & Co., Inc.</u> <hr/> (Last) (First) (Middle) 126 EAST LINCOLN AVENUE <hr/> (Street) RAHWAY NJ 07065 <hr/> (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 01/07/2024	3. Issuer Name and Ticker or Trading Symbol <u>Harpoon Therapeutics, Inc.</u> [HARP] <hr/> 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)	6. Individual or Joint/Group Filing (Check Applicable Line) Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person
---	---	--	--	---

Table I - Non-Derivative Securities Beneficially Owned

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock, par value \$0.0001	0 ⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾	I ⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾	See Footnotes ⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Stock Option (right to buy)	(1)(2)(3)(4)	(1)(2)(3)(4)	Common Stock, par value \$0.0001	0	(1)(2)(3)(4)	I	See Footnotes ⁽¹⁾⁽²⁾⁽³⁾⁽⁴⁾

1. Name and Address of Reporting Person* <u>Merck & Co., Inc.</u> <hr/> (Last) (First) (Middle) 126 EAST LINCOLN AVENUE <hr/> (Street) RAHWAY NJ 07065 <hr/> (City) (State) (Zip)

1. Name and Address of Reporting Person* <u>MERCK SHARP & DOHME LLC</u> <hr/> (Last) (First) (Middle) 126 EAST LINCOLN AVENUE, P.O. BOX 2000 <hr/> (Street) RAHWAY NJ 07065 <hr/> (City) (State) (Zip)

Explanation of Responses:

1. This Form 3 is being filed solely due to the entry by Merck Sharp & Dohme LLC ("Parent") and Hawaii Merger Sub, Inc. ("Purchaser") into Support Agreements (each, a "Support Agreement") with certain stockholders of Harpoon Therapeutics, Inc. (the "Company"). The Support Agreements were entered into in connection with the Agreement and Plan of Merger (the "Merger Agreement"), dated as of January 7, 2024, by and among the Parent, Purchaser and the Company. For additional information regarding the Support Agreements and the Merger Agreement, see the Schedule 13D filed by the Reporting Person with the Securities and Exchange Commission on January 17, 2024 (the "Schedule 13D").

2. Purchaser is a direct wholly-owned subsidiary of Parent and Parent is a direct wholly-owned subsidiary of Merck & Co., Inc. ("Merck", and together with Parent, the "Reporting Persons"). As a result of certain provisions contained in the Support Agreements, the Reporting Persons may be deemed to have beneficial ownership of the shares of common stock covered by the Support Agreements and beneficially owned by the stockholders party thereto (an aggregate of 3,080,815 shares, which represent approximately 17.48% of the Company's total outstanding shares as of the close of business on January 7, 2024, based on the representations made by the Company in the Merger Agreement) for purposes of Section 13(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act").

3. Each of the Reporting Persons declare that the filing of this Form 3 shall not be construed as an admission that the Reporting Persons are the beneficial owners of any securities reported in this Form 3.

4. Generally, upon the exercise of any security convertible or exchangeable for any common stock of the Company by the stockholders party to the Support Agreements, such shares of common stock acquired upon exercise thereof shall be subject to the Support Agreements and the Reporting Persons may be deemed to have beneficial ownership of such additional shares of common stock, if any. The Reporting Persons expressly disclaim any beneficial ownership of the securities reported herein, and the Reporting Persons do not have any pecuniary interest (as defined in Rule 16a-1(a)(2) of the Exchange Act) in any of the shares subject to the Support Agreements.

<u>/s/ Robert M. Davis,</u> <u>Robert M. Davis,</u> <u>Chairman and Chief</u> <u>Executive Officer</u>	<u>01/17/2024</u>
---	-------------------

<u>/s/ Sunil A. Patel, Sunil A.</u> <u>Patel, SVP, Business</u> <u>Development & Licensing</u>	<u>01/17/2024</u>
--	-------------------

** Signature of Reporting Person	Date
-------------------------------------	------

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.